Stockreport

Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

Impel Pharmaceuticals Inc.  (IMPL) 
PDF SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mi [Read more]